The countdown to International MPS Day has begun—learn more here

MPS VI

Maroteaux-Lamy Syndrome

What is MPS VI?

MPS IV is a mucopolysaccharide disease known as Maroteaux-Lamy Syndrome. It takes its name from two French Doctors, Dr. Maroteaux and Dr. Lamy, who first described the condition in 1963. MPS VI has a wide range of symptoms that vary in severity and can be managed and treated with enzyme replacement therapies. There is no cure for MPS VI.

What Causes This Disease?

Mucopolysaccharides are chains of sugar molecules used to build connective tissues in the body.

“muco” refers to the thick jelly-like consistency of the molecules

“poly” means many

“saccharide” is a general term for a sugar molecule

The body constantly replaces used materials and breaks them down for disposal. MPS VI patients are missing an enzyme essential to breaking down the mucopolysaccharide dermatan sulfate. These materials remain stored in the body’s cells, causing progressive damage. Babies may show little sign of the disease, but as cells sustain damage, symptoms start to appear.

To request more information about MPS and related LSD’s please contact us.

Frequently Asked Questions

MPS VI is estimated to occur in 1 in 250,000 to 600,000 newborns.

MPS VI (Maroteaux-Lamy syndrome) is caused by a recessive gene. There is a one in four chance with every pregnancy that the child will inherit the defective gene from each carrier parent and will be affected with the disease. There is a two in three chance that unaffected brothers and sisters of MPS VI children will be carriers.

There is no cure, but treatments such as enzyme replacement therapies can help make MPS VI a more manageable disease. In June 1, 2005, the U.S. Food and Drug Administration (FDA) granted marketing approval for Naglazyme (galsulfase), the first enzyme replacement therapy approved for the treatment of MPS VI.

Join the IMPSN Community

Opt-in today using your email and unlock a wealth of knowledge and support with just one click!